Looking at the universe of stocks we cover at Dividend Channel, on May 28, First Financial Bancorp�(FFBC), Goldman Sachs�(GS) and M & T Bank Corp.�(MTB) will all trade ex-dividend for their respective upcoming dividends. First Financial Bancorp will pay its quarterly dividend of $0.15 on July 1, Goldman Sachs will pay its quarterly dividend of $0.55 on June 27 and M & T Bank�will pay its quarterly dividend of $0.70 on June 30.
START SLIDESHOW:
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen 禄
As a percentage of FFBC’s recent stock price of $16.29, this dividend works out to approximately 0.92%, so look for shares of First Financial Bancorp to trade 0.92% lower — all else being equal — when FFBC shares open for trading on Wednesday. Similarly, investors should look for GS to open 0.34% lower in price and for MTB to open 0.58% lower, all else being equal.
5 Best Dividend Stocks For 2015: Sprint Corp (S&LS)
Sprint Corporation, incorporated on May 10, 2012, offers a range of wireless and wireline communications services to consumers, businesses and government users. On July 10, 2013, the Company, SoftBank Corp. and Sprint Nextel Corporation (Sprint Nextel) completed the merger. In the Merger, Sprint Corporation was merged into Sprint Nextel, New Sprint became the parent company of Sprint Nextel, with Sprint Nextel becoming its direct wholly owned subsidiary, and Sprint Nextel changed its name to Sprint Communications, Inc.
The Company develops, engineers and deploys technologies, including the first wireless fourth generation (4G) service from a national carrier in the United States; offering mobile data services, prepaid brands, including Virgin Mobile USA, Boost Mobile, and Assurance Wireless; instant national and international push-to-talk capabilities, and a global Tier 1 Internet Service. The Company also offers unlimited data services.
Advisors' Opinion:- [By Holly LaFon]
Since Wilmers & Co. took over M&T Bank in 1983 the bank has acquired 23 banks and Savings and Loans (S&Ls) ��expanding from a single state to seven ��and assets have grown from $2 billion to $110 billion. M&T's branch count has grown from 60 to over 870. The bank currently boasts a customer base of over 2 million retail household customers and nearly 220,000 commercial customers.
10 Best Forestry Stocks To Invest In 2014: diaDexus, Inc. (DDXS)
diaDexus, Inc. (diaDexus), incorporated on November 27, 1995, is a medical diagnostics company. The Company is focused on the development and commercialization of in vitro diagnostic products addressing unmet needs in cardiovascular disease. diaDexus�� product, the PLAC Test, helps identify individuals suffering a heart attack or stroke, the #1 and #3 causes of death, respectively in the United States. The PLAC Test measures Lp-PLA2, which is a vascular-specific inflammatory marker implicated in the formation of rupture-prone plaque.
GlaxoSmithKline (GSK) has developed an Lp-PLA2 inhibitor (darapladib) and is testing the drug in two large, global, Phase III clinical trials involving over 27,000 patients to determine if inhibition of the enzyme reduces cardiovascular events. The PLAC Test is a blood test, available nationally through clinical reference, hospital, and advanced cardiovascular diagnostic laboratories.
Advisors' Opinion:- [By Peter Graham]
Small cap stocks Pulse Network Inc (OTCBB: TPNI), Sterling Consolidated Corp (OTCBB: STCC) and diaDexus, Inc (OTCMKTS: DDXS) have or could start to sizzle for investors. However, I should also mention that two of these stocks have been the subject of paid promotions while a third apparently has not been, and could be the real deal. With that in mind, here is a closer look along with a quick reality check about all three small caps to help you decide whether they are hot or not:
- [By Peter Graham]
Small cap medical device or biotech related stocks Therapeutic Solutions International Inc (OTCMKTS: TSOI), diaDexus, Inc (OTCMKTS: DDXS) and Spherix Inc (NASDAQ: SPEX) have been getting some attention lately in various investment newsletters with the good news being that it appears none are the subject of paid promotions from stock promoters. So why are these three stocks all of a sudden getting some attention and what else do you need to know about them before you make a short or a long term bet on one? Here is a closer look at the whole picture and what you might be missing:
10 Best Forestry Stocks To Invest In 2014: ESSA Bancorp Inc. (ESSA)
ESSA Bancorp, Inc. operates as the holding company for ESSA Bank & Trust that provides a range of financial services to individuals, families, and businesses in Pennsylvania. The company provides deposit accounts comprising savings accounts, NOW accounts, checking accounts, money market accounts, club accounts, certificates of deposit, IRAs, and other qualified plan accounts, as well as commercial checking accounts for businesses. It also offers residential first mortgage loans, including one-to-four family residential loans and construction mortgage loans; commercial real estate loans; home equity loans and lines of credit; and commercial and consumer loans, as well as various unsecured or secured loans, loans secured by deposits, personal loans, and automobile loans. In addition, the company provides asset management and trust services, and investment services, as well as insurance benefit consulting services, including health insurance, life insurance, short term and lo ng term disability, dental, vision, and 401(K) retirement planning, as well as individual health products. As of September 30, 2013, it operated 26 full-service banking offices, including 13 offices in Monroe County, 6 offices in Lehigh County, and 7 offices in Northampton County in Pennsylvania. The company was founded in 1916 and is based in Stroudsburg, Pennsylvania.
Advisors' Opinion:- [By Tim Melvin]
Right now I know that silver miners like Pan American Silver (PAAS) and Coeur Mining (CDE) are very cheap on an asset basis. I know that oil and gas producers like Swift Energy (SFY) and WPX Energy (WPX) are priced as if no one will ever use the stuff again. I know that small banks like Cape Bancorp (CBNJ) and Essa Bancorp (ESSA) are crazy-cheap — and if the world does not end, those stocks will be a lot higher in a few years.
- [By Tim Melvin]
I get somewhat amused every day by the thousands of traders who spend all day trying to figure out what the hot stocks like Twitter (TWTR) and Facebook (FB) are going to do every day. Owning stocks like these two banks — or ones I have mentioned before, like ESSA Bancorp (ESSA) and Charter Financial (CHFN) — will be a far more profitable and relaxing endeavor over the next few years.
10 Best Forestry Stocks To Invest In 2014: Celgene Corp (CELG)
Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. The Company�� primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.
The Company invests in research and development, and the drug candidates in its pipeline at various stages of preclinical and clinical development. These candidates include pomalidomide and apremilast, its oral anti-cancer and anti-inflammatory agents, PDA-001, its cellular therapy, oral azacitidine, CC-223 and CC-115 for hematological and solid tumor malignancies, CC-122, its anti-cancer pleiotropic pathway modifier, and ACE-011 and ACE-536 biological products for anemia in several clinical settings of unmet need. Celgene product candidates include Pomalidomide (CC-4047), Oral Anti-Inflammatory: Apremilast (CC-10004), CC-11050, Kinase Inhibitors:Tanzisertib (CC-930), Cellular Therapies: PDA-001, Activin Biology: Sotatercept (ACE-011) ACE-536, and Anti-tumor Agents: CC-22, CC-115, CC-122 and Oral Azacitidine. It owns and operates a manufacturing facility in Zofingen, Switzerland. The Company also owns and operates a drug product manufacturing facility in Boudry, Switzerland.
Commercial! Stage Products
REVLIMID (lenalidomide) is an oral immunomodulatory drug marketed in the United States and many international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma who have received at least one prior therapy. It is also marketed in the United States and certain international markets for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID is distributed in the United States through contracted pharmacies under the RevAssist program, which is a risk-management distribution program. Internationally, REVLIMID is distributed under mandatory risk-management distribution programs.
REVLIMID continues to be evaluated in numerous clinical trials worldwide either alone or in combination with one or more other therapies in the treatment of a range of hematological malignancies, including multiple myeloma (MDS) various lymphomas, chronic lymphocytic leukemia (CLL) other cancers and other diseases. VIDAZA (azacitidine for injection) is a pyrimidine nucleoside. VIDAZA is a Category 1 recommended treatment for patients with intermediate-2 and high-risk MDS and is marketed in the United States for the treatment of all subtypes of MDS. In Europe, VIDAZA is marketed for the treatment of intermediate-2 and high-risk MDS, as well as acute myeloid leukemia (AML) with 30% blasts and has been granted orphan drug designation for the treatment of MDS and AML.
THALOMID (thalidomide) is marketed for patients with newly diagnosed multiple myeloma and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) an inflammatory complication of leprosy and as maintenance therapy for prevention and suppression of the cutaneous manifestation of ENL recurrence. THALOMID is distributed in the United States under its System f! or Thalid! omide Education and Prescribing Safety (S.T.E.P.S.) program. Internationally, THALOMID is also distributed under mandatory risk-management distribution programs. ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) is a solvent-free chemotherapy treatment option for metastatic breast cancer, which was developed using its nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. As of December 31, 2011, ABRAXANE was in various stages of investigation for the treatment of expanded applications for metastatic breast; non-small cell lung; malignant melanoma; pancreatic; bladder and ovarian.
ISTODAX (romidepsin) has received orphan drug designation for the treatment of non-Hodgkin's T-cell lymphomas, which includes CTCL and PTCL. The Company has licensed the worldwide rights (excluding Canada) regarding certain chirally pure forms of methylphenidate for FOCALIN and FOCALIN XR to Novartis. It also licensed to Novartis the rights related to long-acting formulations of methylphenidate and dex-methylphenidate products which are used in FOCALIN XR and RITALIN LA.
Preclinical and Clinical-Stage Pipeline
The product candidates in the Company�� pipeline are at various stages of preclinical and clinical development. Pomalidomide is a small molecule that is orally available and modulates the immune system and other biologically important targets. Pomalidomide is being evaluated in a phase III clinical trial for the treatment of myelofibrosis and a phase III clinical trial evaluating pomalidomide as a treatment for patients with relapsed/refractory multiple myeloma is accruing patients.
The Company is developing a product, ORAL ANTI-INFLAMMATORY AGENTS, which is orally available small molecules that target PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators, including interleukin-2 (IL-2), IL-10, IL-12, IL-23, INF-gamma, TNF-a, leukotrienes,! and nitr! ic oxide synthase. Its investigational drug, apremilast (CC-10004), is used for the treatment of moderate to severe psoriasis and active psoriatic arthritis and is being evaluated in a phase II trial for rheumatoid arthritis and six phase III multi-center international clinical trials. In addition, it is investigating its oral PDE4 inhibitor, CC-11050, which is an anti-inflammatory compound that treat a variety of chronic inflammatory conditions, such as Cutaneous Lupus Erythematosus (CLE).
The Company�� oral kinase inhibitor platform includes inhibitors of the c-Jun N-terminal kinase (JNK) mTOR kinase, spleen tyrosine kinase (Syk) c-fms tyrosine kinase (c-FMS) and DNA-dependent protein kinase (DNAPK). Its oral Syk, c-FMS and DNAPK kinase inhibitors are being investigated in pre-clinical studies. The Company�� new second generation JNK inhibitor, tanzisertib (CC-930), is being evaluated in a phase II trial for the treatment of idiopathic pulmonary fibrosis and a phase II trial for the treatment of discoid lupus is accruing patients. Amrubicin is a third-generation fully synthetic anthracycline molecule with potent topoisomerase II inhibition.
At Celgene Cellular Therapeutics (CCT), it is researching stem cells derived from the human placenta, as well as from the umbilical cord. CCT is the Company�� research and development division. Stem cell based therapies provide disease-modifying outcomes for serious diseases, which lack adequate therapy. It has developed technology for collecting, processing and storing placental stem cells with broad therapeutic applications in cancer, auto-immune diseases, including Crohn's disease, multiple sclerosis, neurological disorders, including stroke and amyotrophic lateral sclerosis (ALS), graft-versus-host disease, and other immunological / anti-inflammatory, rheumatologic and bone disorders.
The Company has collaborated with Acceleron Pharma, Inc. (Acceleron) to develop sotatercept. Two phase I clinical studies have been co! mpleted. ! An additional phase II clinical study has been initiated and is ongoing related to treatments for end-stage renal anemia and to evaluate effects on red blood cell mass and plasma volume.
The Company competes with Abbott Laboratories, Amgen Inc. (Amgen), AstraZeneca PLC., Biogen Idec Inc., Bristol-Myers Squibb Co., Eisai Co., Ltd., F. Hoffmann-LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Pfizer, Sanofi and Takeda Pharmaceutical Co. Ltd. (Takeda).
Advisors' Opinion:- [By WALLSTCHEATSHEET]
Celgene provides products that are seeing increased demand from a growing customer base around that world. The company released a new arthritis drug and is expecting high sales from the treatment. The stock has been surging higher over the last couple of years and is currently trading near highs. Over the last four quarters, earnings have been decreasing while revenues have been rising, leaving investors with conflicting feelings. Relative to its peers and sector, Celgene has led its peers and sector in year-to-date performance by a wide margin. Look for Celgene to continue to OUTPERFORM.
- [By Nicholas Vardy]
It's very much weighted toward some of the bigger stocks in the sector—Gilead Sciences (GILD), Amgen (AMGN), Biogen (BIIB), Celgene Corporation (CELG), Onyx (ONXX), which just received an unsolicited $10 billion bid, just in the past few weeks, and that would be really the best way to minimize your specific or company risk.
- [By David Williamson]
In this video, David Williamson reviews some of his favorite biotech firms. Many analysts have thrown their weight behind Biogen� (NASDAQ: BIIB ) and its new BG12 drug for multiple sclerosis. However, David favors Gilead� (NASDAQ: GILD ) over Biogen since Gilead�has a�larger, more diverse product pipeline. Celgene� (NASDAQ: CELG ) is the No. 1 biotech in David's opinion since it also has blockbuster drugs but a PEG of less than 1.0. Amgen� (NASDAQ: AMGN ) is�a big company with more products in development than most people realize. Overall, for value and future earnings potential, David likes Celgene the best.
10 Best Forestry Stocks To Invest In 2014: Prudential Bancorp Inc. of Pennsylvania(PBIP)
Prudential Bancorp, Inc. of Pennsylvania operates as the holding company for Prudential Savings Bank that provides various financial products and services in Pennsylvania. Its deposit products include interest-bearing and non-interest-bearing checking, money market, savings, and certificate of deposit accounts. The company?s loan portfolio comprises single-family residential mortgage loans, construction and land development loans, non-residential or commercial real estate mortgage loans, home equity loans and lines of credit, commercial business loans, and consumer loans. The company also provides securities and insurance products, as well as automated teller machine and online banking services. As of September 30, 2010, it operated a main office and six branch offices located in Philadelphia and Delaware Counties. The company was founded in 1886 and is headquartered in Philadelphia, Pennsylvania. Prudential Bancorp, Inc. of Pennsylvania is a subsidiary of Prudential Mutu al Holding Company.
Advisors' Opinion:- [By Jim Royal]
I really like to invest in bank demutualizations, and my Special Situations portfolio is back to buy another one: Prudential Bancorp (NASDAQ: PBIP ) . In October, the bank completed its second-step conversion, making it a fully public institution, but it trades at just 73% of tangible book value. That's tremendously cheap for a profitable, albeit slightly, bank. So I'm stepping up to buy the stock.
10 Best Forestry Stocks To Invest In 2014: TCW Strategic Income Fund Inc (TSI)
TCW Strategic Income Fund, Inc. (the Fund), formerly TCW Convertible Securities Fund, Inc., incorporated on January 13, 1987, is a diversified closed-end investment management company. The Fund's investment objective is to seek a total return consisting of current income and capital appreciation by investing in convertible securities, marketable equity securities, investment-grade debt securities, high-yield debt securities, options, and securities issued or guaranteed by the United States Government, its agencies and instrumentalities (U.S. Government Securities). The Fund also invests in repurchase agreements, mortgage-related securities, asset-backed securities, money market securities and other securities.
The Fund may invest in repurchase agreements secured by U.S. Government Securities. The Fund invests in sectors, such as financial services, aerospace and defense, airlines, automobiles, banking, commercial services, electric utilities, insurance, media, utilities, biotechnology and chemicals. The Fund�� investment advisor is TCW Investment Management Company.
Advisors' Opinion:- [By Dividends4Life]
According to a Gabelli Funds report, managed distribution policies offer several advantages, including:1. Lower difference between the fund�� market price and its NAV per share.2. Provides support during periods when the stock market is in a decline.3. Provides a measurable performance target for the investment adviser.Below are several high-yield funds from CEFA that have a managed distribution policy (yields as of December 16):Aberdeen Australia Eqty (IAF)- Distribution Yield: 10.4%- Income Yield: 3.46%Bexil Advisers LLC� (DNI)- Distribution Yield: 11.1%- Income Yield: 3.56%BlackRock En Capital&Inc (CII)- Distribution Yield: 8.78%- Income Yield: 2.34%Cornerstone Strat Value (CLM)- Distribution Yield: 18.77%- Income Yield: 1.83%Cornerstone Total Return (CRF)- Distribution Yield: 19.10%- Income Yield: 0.85%Delaware Inv Div & Inc (DDF)- Distribution Yield: 6.70%- Income Yield: 5.26%Gabelli Equity Trust (GAB)- Distribution Yield: 7.58%- Income Yield: 1.54%Gabelli Utility Trust (GUT)- Distribution Yield: 9.45%- Income Yield: 2.84%MFS Special Value Trust (MFV)- Distribution Yield: 9.60%- Income Yield: 5.73%Nuveen Tx-Adv TR Strat (JTA)- Distribution Yield: 6.70%- Income Yield: 3.12%TCW Strategic Income (TSI)- Distribution Yield: 10.54%- Income Yield: 7.88%Zweig Total Return (ZTR)- Distribution Yield: 7.27%- Income Yield: 1.95%As noted in the Gabelli report, a managed distribution policy may create confusion regarding the true current yield since the reported yield includes the return of capital portion. You can see the disparity above between the income yield and the distribution (reported) yield.If you are looking for a sustainable and growing dividend, you may want to consider some blue-chip dividend stocks such as these with a Free Cash Flow Payout less than 50%, 50+ years of consecutive dividend increases and a 2%+ yield:3M Co. (MMM) is a diversified global company provides enhanced product functionality in electronics, health care, industrial, consumer
10 Best Forestry Stocks To Invest In 2014: Bio-Rad Laboratories Inc. (BIO)
Bio-Rad Laboratories, Inc. manufactures and supplies the life science research, healthcare, analytical chemistry, and other markets worldwide with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze, and purify their components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, sells, and services reagents, apparatus, and instruments used for biological research. This segment sells its products to university and medical school laboratories, pharmaceutical and biotechnology companies, food testing laboratories, and government and industrial research facilities. The Clinical Diagnostics segment develops, manufactures, sells, and services automated test systems, informatics systems, test kits, and specialized quality controls for the healthcare market. This segment sells its products to reference laboratories, hospital laboratories, screening faci lities, physicians? office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company was founded in 1952 and is headquartered in Hercules, California.
Advisors' Opinion:- [By Seth Jayson]
Bio-Rad Laboratories (NYSE: BIO ) reported earnings on May 7. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Bio-Rad Laboratories met expectations on revenues and whiffed on earnings per share. - [By Victor Selva]
Bio-Rad Laboratories Inc. (BIO) is a manufacturer and distributor of its own life science research and clinical diagnostics products. The company has two primary segments: Life Science and Clinical Diagnostics. The company sells its products and services to a diverse client base comprised of scientific research, healthcare, education and government customers.
No comments:
Post a Comment